What is Pandorum?
Pandorum Technologies operates at the intersection of advanced biotechnology and clinical research, specializing in the creation of functional human tissues. By leveraging sophisticated cellular engineering and 3D printing techniques, the company develops bio-engineered corneas, mini livers, and lung regeneration therapies. This innovative approach addresses critical gaps in drug discovery and regenerative medicine, positioning Pandorum as a key player in the global healthcare technology landscape. By targeting both research institutions and clinical therapeutic markets, the firm is effectively bridging the gap between laboratory-scale innovation and scalable medical solutions, ensuring that its advancements in tissue engineering meet rigorous safety and efficacy standards for future patient care.
How much funding has Pandorum raised?
Pandorum has raised a total of $29M across 2 funding rounds:
Other Financing Round
$11M
Series B
$18M
Other Financing Round (2024): $11M with participation from Indian Angel Network
Series B (2026): $18M led by Galentic Pharma Pvt and Avinya Ventures
Key Investors in Pandorum
Indian Angel Network
A prominent network of angel investors providing early-stage capital and strategic mentorship to high-potential ventures.
Avinya Ventures
A SEBI-approved venture capital fund that supports innovative startups across various sectors with a focus on founder-market fit.
Galentic Pharma Pvt
A specialized pharmaceutical manufacturer with a global footprint, focusing on sterile ophthalmic and dermatological healthcare solutions.
What's next for Pandorum?
With this latest round of financing, Pandorum is well-positioned to accelerate its clinical trial pipelines and expand its manufacturing capabilities for bio-engineered tissues. The strategic focus will likely shift toward scaling production to meet the demands of global healthcare organizations and pharmaceutical partners. As the company matures, the integration of its regenerative therapies into mainstream medical practice will be the primary driver of long-term value. Investors are closely monitoring the firm's ability to navigate regulatory pathways while maintaining its competitive edge in the high-growth sector of bio-manufacturing and personalized medicine.
See full Pandorum company page
